What question did this study set out to answer?

The aim is to explore the adoption of whole genome sequencing (WGS) and transcriptome sequencing (WTS) as routine healthcare practices for cancer patients.

April 10, 2026Open Access

Implementing whole genome and transcriptome sequencing for cancer patients in routine healthcare: a comprehensive guide to costing

Key Points

The aim is to explore the adoption of whole genome sequencing (WGS) and transcriptome sequencing (WTS) as routine healthcare practices for cancer patients.
Reviewing cost structures of WGS/WTS tests
Analyzing the current pricing of consumables
Assessing clinical implementation processes
Lower costs of consumables are likely to improve adoption rates of WGS/WTS
WGS/WTS can be integrated into clinical settings more feasibly
Potential enhancement of personalized cancer treatment options

Abstract

Thus, falling prices of consumables would facilitate the broad implementation of WGS/WTS as a clinical-grade test.

Bookmark

View Full Paper